Department of Medicine Archives
Jan. 9, 2019—Three members of the School for Science and Math at Vanderbilt’s senior class are semifinalists in the Regeneron Science Talent Search.
Jan. 4, 2019—Craig Lindsley, co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been named a fellow of the National Academy of Inventors.
Dec. 13, 2018—The grant will support Mary Philip's research to develop an organoid model — a miniature cell model of a functioning organ — of the liver to enable three-dimensional observation of immune-cancer interactions at the single-cell level at the earliest stages of cancer development.
Nov. 16, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have identified several of the conditions that arise and have determined that they usually appear early in treatment.
Oct. 26, 2018—A new link between a support protein within the brain's white matter and known Alzheimer's biomarkers discovered by Angela Jefferson and colleagues bring researchers a step toward earlier and more precise detection of neuropathology underlying cognitive impairment that may lead to new targeted therapies
Oct. 11, 2018—Loss of a protein that regulates mitochondrial function can greatly increase the risk of a heart attack, report Eric Gamazon, Sandra Zinkel and graduate students Christie Salisbury-Ruf and Clinton Bertram in new research.
Oct. 4, 2018—An international team led by researchers at Vanderbilt University Medical Center sheds new light on the cause of pulmonary fibrosis and demonstrates a way to impede the disease.
Sep. 27, 2018—A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer, the third most common cancer among both men and women in the United States.
Sep. 13, 2018—Researchers led by melanoma researcher Douglas Johnson have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.